{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:59:44Z","timestamp":1792803584496,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jvacx.2024.100604","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:54:41Z","timestamp":1734483281000},"page":"100604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Current status of the development of dengue vaccines"],"prefix":"10.1016","volume":"22","author":[{"given":"Michelle Felicia","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiau Ming","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2093","article-title":"Prevalence and burden of dengue infection in Europe: a systematic review and meta-analysis","volume":"30","author":"Ahmed","year":"2020","journal-title":"Rev Med Virol"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100604_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008349","article-title":"Dengue in a crowded megacity: lessons learnt from 2019 outbreak in Dhaka, Bangladesh","volume":"14","author":"Hossain","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jvacx.2024.100604_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2021.04.010","article-title":"Co-circulation of three dengue virus serotypes led to a severe dengue outbreak in Xishuangbanna, a border area of China, Myanmar, and Laos, in 2019","volume":"107","author":"Zhang","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0020","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat Microbiol"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100604_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26226768","article-title":"Updates on dengue vaccine and antiviral: where are we heading?","volume":"26","author":"Norshidah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jvacx.2024.100604_bb0030","unstructured":"Dengue - Global situation. 2024 [cited 2024 25 October]."},{"issue":"12 Suppl","key":"10.1016\/j.jvacx.2024.100604_bb0035","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tim.2010.04.003","article-title":"Targeting a host process as an antiviral approach against dengue virus","volume":"18","author":"Sayce","year":"2010","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0065-3527(03)59009-1","article-title":"Microevolution and virulence of dengue viruses","volume":"59","author":"Rico-Hesse","year":"2003","journal-title":"Adv Virus Res"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100604_bb0050","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/trstmh\/traa007","article-title":"Persistence of symptoms in dengue patients: a clinical cohort study","volume":"114","author":"Tiga-Loza","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tim.2013.12.011","article-title":"Global spread of dengue virus types: mapping the 70 year history","volume":"22","author":"Messina","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0065","doi-asserted-by":"crossref","first-page":"29201","DOI":"10.1038\/srep29201","article-title":"Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses","volume":"6","author":"Flipse","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/JVI.01826-10","article-title":"An in-depth analysis of original antigenic sin in dengue virus infection","volume":"85","author":"Midgley","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Ann Rev Microbiol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0080","series-title":"Role of the dengue virus 5'and 3'untranslated regions in viral replication","author":"Gamarnik","year":"2010"},{"key":"10.1016\/j.jvacx.2024.100604_bb0085","first-page":"14","article-title":"Translation and processing of the dengue virus polyprotein","author":"Padmanabhan","year":"2010","journal-title":"Front Dengue Virus Res"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/v9060137","article-title":"The 5\u2032 and 3\u2019 untranslated regions of the Flaviviral genome","volume":"9","author":"Ng","year":"2017","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100604_bb0095","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/jvi.69.11.7232-7243.1995","article-title":"Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum","volume":"69","author":"Falgout","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0100","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.5068","article-title":"Using bioinformatics tools for the discovery of dengue RNA-dependent RNA polymerase inhibitors","volume":"6","author":"Nncube","year":"2018","journal-title":"PeerJ"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/v9040091","article-title":"Dengue virus non-structural protein 5","volume":"9","author":"El Sahili","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jvacx.2024.100604_bb0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bcp.2018.04.008","article-title":"Dengue virus NS2 and NS4: minor proteins, mammoth roles","volume":"154","author":"Gopala Reddy","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0115","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01985-18","article-title":"The dengue virus nonstructural protein 1 (NS1) is secreted from mosquito cells in association with the intracellular cholesterol transporter chaperone Caveolin complex","volume":"93","author":"Rosales Ramirez","year":"2019","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0120","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1038\/s41598-019-39157-7","article-title":"Dengue virus nonstructural 3 protein interacts directly with human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reduces its glycolytic activity","volume":"9","author":"Silva","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0125","first-page":"178","article-title":"Dengue vaccine: Global development update","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"9951","key":"10.1016\/j.jvacx.2024.100604_bb0130","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019368","article-title":"Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis","volume":"9","author":"Rosa","year":"2019","journal-title":"BMJ Open"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100604_bb0145","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"10234","key":"10.1016\/j.jvacx.2024.100604_bb0150","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41541-023-00658-2","article-title":"Is new dengue vaccine efficacy data a relief or cause for concern?","volume":"8","author":"Thomas","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan-dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100604_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","article-title":"Antibody-dependent enhancement (ADE) and the role of complement system in disease pathogenesis","volume":"152","author":"Thomas","year":"2022","journal-title":"Mol Immunol"},{"issue":"86","key":"10.1016\/j.jvacx.2024.100604_bb0170","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2013.0414","article-title":"Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity","volume":"10","author":"Reich","year":"2013","journal-title":"J R Soc Interface"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/infdis\/jit436","article-title":"A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand","volume":"209","author":"Anderson","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0180","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4269\/ajtmh.14-0132","article-title":"Review article: research on dengue during world war II revisited","volume":"91","author":"Snow","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0185","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4269\/ajtmh.1989.40.444","article-title":"Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever","volume":"40","author":"Kliks","year":"1989","journal-title":"Am J Trop Med Hyg"},{"issue":"5979","key":"10.1016\/j.jvacx.2024.100604_bb0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jvacx.2024.100604_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.580096","article-title":"Intrinsic ADE: the dark side of antibody dependent enhancement during dengue infection","volume":"10","author":"Narayan","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/tra.12012","article-title":"Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans","volume":"14","author":"Flipse","year":"2013","journal-title":"Traffic"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0205","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nm887","article-title":"Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever","volume":"9","author":"Mongkolsapaya","year":"2003","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0210","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.4049\/jimmunol.176.5.2817","article-title":"Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes","volume":"176","author":"Bashyam","year":"2006","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0215","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"9284","key":"10.1016\/j.jvacx.2024.100604_bb0225","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(01)05967-0","article-title":"Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study","volume":"358","author":"Bista","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2024.100604_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840104","article-title":"Current development and challenges of tetravalent live-attenuated dengue vaccines","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0235","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue Serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jvacx.2024.100604_bb0245","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100604_bb0250","first-page":"10","article-title":"Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data","author":"Laydon","year":"2021","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100604_bb0255","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0260","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0265","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100604_bb0270","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00440-18","article-title":"Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and -4","volume":"92","author":"Barban","year":"2018","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.jvacx.2024.100604_bb0275","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0280","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100604_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102598","article-title":"Qdenga\u00ae - a promising dengue fever vaccine; can it be recommended to non-immune travelers?","volume":"54","author":"Angelin","year":"2023","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0290","doi-asserted-by":"crossref","first-page":"e1350","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0295","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0300","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in Flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"issue":"10234","key":"10.1016\/j.jvacx.2024.100604_bb0305","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0310","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0315","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0320","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0325","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.virol.2005.06.009","article-title":"Role of RNA structures present at the 3\u2019UTR of dengue virus on translation, RNA synthesis, and viral replication","volume":"339","author":"Alvarez","year":"2005","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0330","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0335","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following Administration of a Single Dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0345","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0350","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0355","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0360","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4269\/ajtmh.14-0819","article-title":"Safety and immunogenicity of a dengue virus Serotype-1 purified-inactivated vaccine: results of a phase 1 clinical trial","volume":"93","author":"Martinez","year":"2015","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0365","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","article-title":"Safety and immunogenicity of an AS03 B -Adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy U.S. adults: a phase 1\/2 randomized study","volume":"103","author":"Lin","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0370","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.jvacx.2024.100604_bb0375","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100604_bb0380","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.vaccine.2011.01.077","article-title":"Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys","volume":"29","author":"Maves","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0385","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"33","key":"10.1016\/j.jvacx.2024.100604_bb0390","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.jvacx.2024.100604_bb0395","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0400","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jvacx.2024.100604_bb0405","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fimmu.2020.01055","article-title":"Challenges in dengue vaccines development: pre-existing infections and cross-reactivity","volume":"11","author":"Izmirly","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0976500X231204401","article-title":"Dengue virus: molecular biology and recent developments in control strategies, prevention, management, and therapeutics","volume":"14","author":"Hershan","year":"2023","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0415","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cben.201600002","article-title":"Production and purification of recombinant proteins from Escherichia coli","volume":"3","author":"Tripathi","year":"2016","journal-title":"ChemBioEng Reviews"},{"key":"10.1016\/j.jvacx.2024.100604_bb0420","article-title":"Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study","volume":"99","author":"Miauton","year":"2023","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100604_bb0425","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02482-20","article-title":"A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0430","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jvacx.2024.100604_bb0435","article-title":"Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia\u00ae) in the state of Paran\u00e1, Brazil: integrating case-cohort and case-control designs","volume":"35","author":"Diaz-Quijano","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"9","key":"10.1016\/j.jvacx.2024.100604_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008676","article-title":"Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine","volume":"14","author":"Ahmed","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100604_bb0445","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.jvacx.2024.100604_bb0450","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S1473-3099(19)30642-5","article-title":"Infectious disease crisis in the Philippines","volume":"19","author":"Diseases","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0455","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0460","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0465","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100604_bb0470","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0475","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0480","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","article-title":"Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2032 noncoding region and nonstructural proteins 1 and 3","volume":"74","author":"Butrapet","year":"2000","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0485","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-021-00340-5","article-title":"Attenuated dengue viruses are genetically more diverse than their respective wild-type parents","volume":"6","author":"Bifani","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0490","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"issue":"23\u201324","key":"10.1016\/j.jvacx.2024.100604_bb0495","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"Kanesa-thasan","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/infdis\/170.1.27","article-title":"Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine","volume":"170","author":"Dharakul","year":"1994","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"10.1016\/j.jvacx.2024.100604_bb0510","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0515","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","article-title":"Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques","volume":"84","author":"Osorio","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100604_bb0520","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0525","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0530","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2032 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"J Virol"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100604_bb0535","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27\u201330","key":"10.1016\/j.jvacx.2024.100604_bb0540","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/S0264-410X(03)00488-2","article-title":"Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys","volume":"21","author":"Whitehead","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0545","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2019-UTR) or by exchange of the DENV-3 3\u2019-UTR with that of DENV-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0550","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2032-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0555","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4269\/ajtmh.2008.79.678","article-title":"Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity","volume":"79","author":"McArthur","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0560","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/JVI.76.2.525-531.2002","article-title":"Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes","volume":"76","author":"Hanley","year":"2002","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0565","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"Troyer","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"330","key":"10.1016\/j.jvacx.2024.100604_bb0570","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0580","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the National Institute of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100604_bb0585","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2101","article-title":"Dengue: status of current and under-development vaccines","volume":"30","author":"Redoni","year":"2020","journal-title":"Rev Med Virol"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020528","article-title":"DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III","volume":"6","author":"Azevedo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100604_bb0600","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent developments in recombinant protein-based dengue vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2024.100604_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"50","key":"10.1016\/j.jvacx.2024.100604_bb0610","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0615","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: Progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0620","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100604_bb0625","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1381612823666170913163904","article-title":"Development of peptide vaccines in dengue","volume":"24","author":"Reginald","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10989-022-10402-4","article-title":"Design of an Epitope-Based Peptide Vaccine against Dengue Virus Isolate from eastern Uttar Pradesh, India","volume":"28","author":"Gupta","year":"2022","journal-title":"Int J Pept Res Ther"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100604_bb0635","article-title":"Designing an epitope-based peptide vaccine derived from RNA-dependent RNA polymerase (RdRp) against dengue virus serotype 2","volume":"10","author":"Wahongan","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0640","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.jvacx.2024.100604_bb0645","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1016\/j.vaccine.2011.03.002","article-title":"Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0650","article-title":"Enhancement of tetravalent immune responses to highly conserved epitopes of a dengue peptide vaccine conjugated to polystyrene nanoparticles","volume":"8","author":"Chan","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0655","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2024.100604_bb0660","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect Guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0665","doi-asserted-by":"crossref","DOI":"10.15190\/d.2022.9","article-title":"mRNA-based vaccine technology for HIV","volume":"10","author":"Fortner","year":"2022","journal-title":"Discoveries (Craiova)"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0670","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41541-023-00752-5","article-title":"Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection","volume":"8","author":"Kackos","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"22","key":"10.1016\/j.jvacx.2024.100604_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213911","article-title":"Engineering modified mRNA-based vaccine against dengue virus using computational and reverse vaccinology approaches","volume":"23","author":"Mukhtar","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jvacx.2024.100604_bb0680","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","article-title":"A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice","volume":"37","author":"He","year":"2022","journal-title":"Virol Sin"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100604_bb0685","first-page":"362","article-title":"The recent development of dengue vaccine: a review","volume":"6","author":"Zainul","year":"2024","journal-title":"J Med Pharmaceut Chem Res"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0690","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100604_bb0695","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virol.2008.08.008","article-title":"Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model","volume":"380","author":"Kyle","year":"2008","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100604_bb0700","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.virol.2012.10.007","article-title":"New generation humanized mice for virus research: comparative aspects and future prospects","volume":"435","author":"Akkina","year":"2013","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100604_bb0705","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","article-title":"Humanized mice for immune system investigation: progress, promise and challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"50","key":"10.1016\/j.jvacx.2024.100604_bb0710","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1016\/j.vaccine.2015.09.052","article-title":"Dengue human infection models to advance dengue vaccine development","volume":"33","author":"Larsen","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100604_bb0715","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4161\/hv.24188","article-title":"Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development","volume":"9","author":"Thomas","year":"2013","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:58:50Z","timestamp":1737727130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":143,"alternative-id":["S2590136224001773"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100604","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of the development of dengue vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100604"}}